Business Description
OS Therapies Inc
NAICS : 541714
SIC : 2834
ISIN : US68764Y2072
Total Employee Number:
5Description
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.68 | |||||
Equity-to-Asset | -1.48 | |||||
Debt-to-Equity | -0.12 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -63.5 | |||||
3-Year EPS without NRI Growth Rate | -47.9 | |||||
3-Year FCF Growth Rate | -38.6 | |||||
3-Year Book Growth Rate | 42.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.09 | |||||
9-Day RSI | 41.11 | |||||
14-Day RSI | 43.11 | |||||
3-1 Month Momentum % | 1.69 | |||||
6-1 Month Momentum % | 22.45 | |||||
12-1 Month Momentum % | 4.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.05 | |||||
Quick Ratio | 0.05 | |||||
Cash Ratio | 0.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.7 | |||||
Shareholder Yield % | 22.68 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -468.43 | |||||
ROIC % | -585 | |||||
3-Year ROIIC % | -701.97 | |||||
ROC (Joel Greenblatt) % | -1099968.75 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 5.84 | |||||
EV-to-EBIT | -1.94 | |||||
EV-to-EBITDA | -1.96 | |||||
EV-to-Forward-Revenue | 10.81 | |||||
EV-to-FCF | -4.35 | |||||
Earnings Yield (Greenblatt) % | -51.55 | |||||
FCF Yield % | -23.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:OSTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OS Therapies Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.08 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 60.25 | ||
| 14-Day RSI | 43.11 | ||
| 14-Day ATR ($) | 0.128542 | ||
| 20-Day SMA ($) | 1.667 | ||
| 12-1 Month Momentum % | 4.05 | ||
| 52-Week Range ($) | 1.15 - 2.57 | ||
| Shares Outstanding (Mil) | 44.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OS Therapies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OS Therapies Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-17 | In 113 days | ||
| General meeting for 2026 | 2026-10-14 10:00 | In 80 days | ||
| Second quarter earnings results for 2026 | 2026-08-19 | In 23 days | ||
| First quarter earnings results for 2026 | 2026-05-18 | 1.88 (-1.57%) | ||
| OST-HER2 immune pharmacodynamic response biomarkers | 2026-04-30 08:30 | 1.63 (-0.61%) | ||
| Annual report for 2025 | 2026-03-31 | 1.33 (-5.67%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 1.33 (-5.67%) | ||
| Third quarter earnings results for 2025 | 2025-11-17 | 1.80 (+0.00%) | ||
| General meeting for 2025 | 2025-10-14 10:00 | 1.95 (+0.52%) | ||
| Investor Conference Call | 2025-10-13 08:30 | 1.99 (-5.24%) |
Show
Entries
OS Therapies Inc Frequently Asked Questions
What is OS Therapies Inc(OSTX)'s stock price today?
The current price of OSTX is $1.52. The 52 week high of OSTX is $2.57 and 52 week low is $1.15.
When is next earnings date of OS Therapies Inc(OSTX)?
The next earnings date of OS Therapies Inc(OSTX) is 2026-08-19 Est..
Does OS Therapies Inc(OSTX) pay dividends? If so, how much?
OS Therapies Inc(OSTX) does not pay dividend.
Guru Commentaries on AMEX:OSTX
No articles.
Press Release
Articles on OS Therapies Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers